BioNTech (NASDAQ: BNTX) CEO sells all direct shares under trading plan

What happened

BioNTech SE (NASDAQ: BNTX) said Chief Executive Officer and 10% owner Ugur Sahin sold 63,209 ordinary shares on 2026-10-08 and 2026-10-09.

He sold 27,000 shares at $92.31 on 2026-10-08 and 36,209 shares at $95.37 on 2026-10-09, for about $5.95 million.

The Form 4 says the trades were made under a Rule 10b5-1 trading plan set up on June 3, 2026.

After the sales, Sahin held 0 directly owned shares.

Key numbers

Metric	Latest	Change	Source
Shares sold	63,209 ordinary shares		SEC Form 4
Total sale proceeds	about $5.95 million		SEC Form 4
Lowest sale price	$92.31 per share		SEC Form 4
Highest sale price	$95.37 per share		SEC Form 4
Post-sale direct holding	0 shares		SEC Form 4

Read more: BioNTech (BNTX) stock analysis and investment case

Why it matters

OptimistFi's case is that BioNTech is a cash-rich COVID-windfall reinvestment story.

The stock works only if its mRNA and immunotherapy platform becomes a durable non-COVID oncology business before vaccine cash flows and R&D losses erode value.

This filing does not change that operating test.

It does show that Sahin's direct stake fell to zero.

OptimistFi's calculation shows the 63,209 shares were 100.0% of Sahin's pre-sale direct holding.

That makes this a clean ownership update, not a business update.

The direct sale to zero matters because it removes one visible ownership line from a company whose value still depends on a durable non-COVID business.

BioNTech still has to prove that platform before vaccine cash flows fade.

The filing also still shows 39,218,111 ordinary shares held indirectly through Medine GmbH.

It says 106,721 of the ordinary shares are held for the benefit of an individual under a trust arrangement.

So the ownership picture is mixed. The direct holding is gone, but the indirect block remains.

For investors, that keeps this in the ownership lane while the business case still turns on execution.

Related: BioNTech Ends Cancer-Vaccine Trial, Raising Stakes for Oncology

What's next

The June 3, 2026 Rule 10b5-1 plan is the key frame for any later trades.

Any future Form 4 under that plan would show whether Sahin keeps selling or has finished the planned transactions.

More sales would extend the planned-selling signal.

No further sales would leave this as a completed direct exit.

If later filings show no additional sales, the direct exit stays limited to this report.

More from OptimistFi